2017 Advances in Cancer Types & Treatment
GASTROINTESTINAL
Esophageal adenocarcinoma: novel tool predicts nCRT survival benefit
This study developed and validated a novel calculator for esophageal adenocarcinoma that reasonably predicts which patients are expected to derive OS benefit from neoadjuvant chemoradiation (nCRT).
BREAST
Breast cancer: beta-blockers fail to improve survival
Beta-blockers do not affect breast cancer recurrence, overall deaths (ODs) or cancer-specific deaths (CSDs), according to a meta-analysis.
LUNG
ASCO clinical cancer advances 2017: non-small cell lung cancer.
Programmed death-1 (PD-1) checkpoint inhibitors improve survival in advanced NSCLC compared with chemotherapy, and are more tolerable for most patients.
Happy & Healthy Living to all! more